Alto Neuroscience (ANRO) Cash from Financing Activities (2023 - 2026)

Alto Neuroscience has reported Cash from Financing Activities for 4 years, with the latest figure at $114.9 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 1159.35% year-over-year to $114.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $165.9 million (up 1517.04% YoY) and the FY2025 annual result came in at $60.1 million, down 55.72% from the prior year.
• Cash from Financing Activities rose to $114.9 million in Q1 2026 per ANRO's latest filing, from $50.2 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $134.6 million in Q1 2024 and troughed at -$234000.0 in Q2 2024.
• A 4-year average of $29.1 million and a median of $1.3 million in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities sank 358.82% in 2024, then soared 102318.37% in 2025.
• Over 4 years, Cash from Financing Activities stood at $43.1 million in 2023, then tumbled by 99.89% to $49000.0 in 2024, then jumped by 102318.37% to $50.2 million in 2025, then jumped by 129.03% to $114.9 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $114.9 million, $50.2 million, and $153000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.